Carcinoma News and Research RSS Feed - Carcinoma News and Research

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
New technique can help identify aggressive forms of DCIS

New technique can help identify aggressive forms of DCIS

When a woman is diagnosed with the earliest stage of breast cancer, how aggressive should her treatment be? Will the non-invasive cancer become invasive? Or is it a slow-growing variety that will likely never be harmful? [More]
Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial, presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Study focuses on critical proteins involved in ovarian cancer biology

Study focuses on critical proteins involved in ovarian cancer biology

In what is believed to be the largest study of its kind, scientists at the Pacific Northwest National Laboratory, Johns Hopkins University and their collaborators from institutions across the nation have examined the collections of proteins in the tumors of 169 ovarian cancer patients to identify critical proteins present in their tumors. [More]
Immunotherapy-treated cancer patients may develop rheumatic disorders

Immunotherapy-treated cancer patients may develop rheumatic disorders

Oncologists need to be aware of the potential for rheumatological diseases in patients with cancer following treatment with immune checkpoint inhibitors, say US investigators. [More]
Compounds extracted from parsley and dill seeds may help fight cancer

Compounds extracted from parsley and dill seeds may help fight cancer

A team of Russian scientists from Moscow Institute of Physics and Technology, the N. D. Zelinsky Institute of Organic Chemistry, the Institute of Developmental Biology, and the Institute of Cell Biophysics proposed an efficient approach to a novel agents with anticancer activity. [More]
Scientists find link between makeup of individual's microbiome and head and neck cancer

Scientists find link between makeup of individual's microbiome and head and neck cancer

In a sample study, researchers at Johns Hopkins say they have found an association between the makeup of an individual's microbiome and head and neck cancer, a finding that potentially advances the quest for faster and more accurate cancer diagnosis and therapy. [More]
Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Case reports on 13 cancer patients suggest that a small number of cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at some higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns Hopkins Medicine researchers. [More]
HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate. [More]
Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital. [More]
Cabozantinib extends advanced RCC overall survival

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus. [More]
ERCC2 validated as chemotherapy response biomarker in bladder cancer

ERCC2 validated as chemotherapy response biomarker in bladder cancer

Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma. [More]
Study provides valuable insight into biology of tumours in early stages of cancer

Study provides valuable insight into biology of tumours in early stages of cancer

Bladder cancer is a frequent disease affecting approximately 1,900 persons in Denmark annually. A high number of these patients only have superficial tumours in the bladder when the disease is diagnosed. [More]
Immunotherapy drugs given after chemotherapy may benefit ovarian cancer patients

Immunotherapy drugs given after chemotherapy may benefit ovarian cancer patients

Women with advanced ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy, according to a new study published in Clinical Cancer Research today. [More]
Novel enzyme immunoassay helps diagnose HCV infection in one simple step

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable. [More]
Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. [More]
Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Hepatocellular carcinoma, the most common type of liver cancer, is increasing in incidence in the United States, and infection with the Hepatitis B virus (HBV) causes about 50 percent of cases. [More]
New technique helps identify link between fatty acids and breast cancer in postmenopausal women

New technique helps identify link between fatty acids and breast cancer in postmenopausal women

The presence of high saturated fatty acids in breast tissue may be a useful indicator of cancer in postmenopausal women, according to a new study by researchers at NYU Langone Medical Center, published online June 7 in Radiology, a journal of the Radiological Society of North America. [More]
Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Data presented today at the American Society of Clinical Oncology congress showed that cabozantinib, a next generation tyrosine kinase inhibitor (TKI) can extend the lives of patients by nearly two years following failure of one or more anti-angiogenic therapies almost five months longer than everolimus, a current standard of care therapy. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
New research reveals advances that could change gynecologic cancer standard-of-care treatments

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology. [More]
Advertisement